Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 15, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 281 Common Stock at $540.48 ($151,874) on October 15, 2026; holds 333,662 after (Indirect).
- Open-market sale: disposed of 1,163 Common Stock at $541.59 ($629,864) on October 15, 2026; holds 332,499 after (Indirect).
- Open-market sale: disposed of 456 Common Stock at $542.68 ($247,462) on October 15, 2026; holds 332,043 after (Indirect).
- Open-market sale: disposed of 371 Common Stock at $543.39 ($201,599) on October 15, 2026; holds 331,672 after (Indirect).
- Open-market sale: disposed of 269 Common Stock at $544.75 ($146,539) on October 15, 2026; holds 331,403 after (Indirect).
- Open-market sale: disposed of 825 Common Stock at $545.87 ($450,347) on October 15, 2026; holds 330,578 after (Indirect).
- Open-market sale: disposed of 601 Common Stock at $546.94 ($328,713) on October 15, 2026; holds 329,977 after (Indirect).
- Open-market sale: disposed of 2,166 Common Stock at $547.83 ($1,186,593) on October 15, 2026; holds 327,811 after (Indirect).
- Open-market sale: disposed of 2,039 Common Stock at $548.89 ($1,119,183) on October 15, 2026; holds 325,772 after (Indirect).
- Open-market sale: disposed of 1,009 Common Stock at $549.76 ($554,704) on October 15, 2026; holds 324,763 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $550.72 ($110,143) on October 15, 2026; holds 324,563 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $551.50 ($66,180) on October 15, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 15, 2026; holds 223,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,193,200 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-15 | Open-market sale | Common Stock | 281 | $540 | $151.9K | 333,662 |
| 2026-10-15 | Open-market sale | Common Stock | 1,163 | $542 | $629.9K | 332,499 |
| 2026-10-15 | Open-market sale | Common Stock | 456 | $543 | $247.5K | 332,043 |
| 2026-10-15 | Open-market sale | Common Stock | 371 | $543 | $201.6K | 331,672 |
| 2026-10-15 | Open-market sale | Common Stock | 269 | $545 | $146.5K | 331,403 |
| 2026-10-15 | Open-market sale | Common Stock | 825 | $546 | $450.3K | 330,578 |
| 2026-10-15 | Open-market sale | Common Stock | 601 | $547 | $328.7K | 329,977 |
| 2026-10-15 | Open-market sale | Common Stock | 2,166 | $548 | $1.2M | 327,811 |
| 2026-10-15 | Open-market sale | Common Stock | 2,039 | $549 | $1.1M | 325,772 |
| 2026-10-15 | Open-market sale | Common Stock | 1,009 | $550 | $554.7K | 324,763 |
| 2026-10-15 | Open-market sale | Common Stock | 200 | $551 | $110.1K | 324,563 |
| 2026-10-15 | Open-market sale | Common Stock | 120 | $552 | $66.2K | 324,443 |
| 2026-10-15 | Option exercise/conversion | Stock Option | 9,500 | — | — | 223,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (9,500 shares) |
| 2026-10-15 | Open-market sale (281 shares) |
| 2026-10-15 | Open-market sale (1,163 shares) |
| 2026-10-15 | Open-market sale (456 shares) |
| 2026-10-15 | Open-market sale (371 shares) |
| 2026-10-15 | Open-market sale (269 shares) |
| 2026-10-15 | Open-market sale (825 shares) |
| 2026-10-15 | Open-market sale (601 shares) |
| 2026-10-15 | Open-market sale (2,166 shares) |
| 2026-10-15 | Open-market sale (2,039 shares) |
| 2026-10-15 | Open-market sale (1,009 shares) |
| 2026-10-15 | Open-market sale (200 shares) |
| 2026-10-15 | Open-market sale (120 shares) |
| 2026-10-15 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.